AU2002333018B2 - Modulation of physiological processes and agents useful for same - Google Patents

Modulation of physiological processes and agents useful for same Download PDF

Info

Publication number
AU2002333018B2
AU2002333018B2 AU2002333018A AU2002333018A AU2002333018B2 AU 2002333018 B2 AU2002333018 B2 AU 2002333018B2 AU 2002333018 A AU2002333018 A AU 2002333018A AU 2002333018 A AU2002333018 A AU 2002333018A AU 2002333018 B2 AU2002333018 B2 AU 2002333018B2
Authority
AU
Australia
Prior art keywords
glutathione
mammal
schizophrenia
brain
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002333018A
Other languages
English (en)
Other versions
AU2002333018A1 (en
Inventor
Michael Berk
Ashley I. Bush
David L. Copolov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mental Health Research Institute of Victoria
Original Assignee
Mental Health Research Institute of Victoria
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23266273&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2002333018(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mental Health Research Institute of Victoria filed Critical Mental Health Research Institute of Victoria
Publication of AU2002333018A1 publication Critical patent/AU2002333018A1/en
Application granted granted Critical
Publication of AU2002333018B2 publication Critical patent/AU2002333018B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002333018A 2001-09-27 2002-09-26 Modulation of physiological processes and agents useful for same Ceased AU2002333018B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32506101P 2001-09-27 2001-09-27
US60/325,061 2001-09-27
PCT/AU2002/001320 WO2003026684A1 (en) 2001-09-27 2002-09-26 Modulation of physiological processes and agents useful for same

Publications (2)

Publication Number Publication Date
AU2002333018A1 AU2002333018A1 (en) 2003-06-26
AU2002333018B2 true AU2002333018B2 (en) 2006-08-31

Family

ID=23266273

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002333018A Ceased AU2002333018B2 (en) 2001-09-27 2002-09-26 Modulation of physiological processes and agents useful for same

Country Status (10)

Country Link
US (3) US20050032708A1 (enExample)
EP (1) EP1438063B1 (enExample)
JP (3) JP4684553B2 (enExample)
AT (1) ATE468129T1 (enExample)
AU (1) AU2002333018B2 (enExample)
CA (1) CA2461703C (enExample)
DE (1) DE60236446D1 (enExample)
DK (1) DK1438063T3 (enExample)
ES (1) ES2346859T3 (enExample)
WO (1) WO2003026684A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9630937B2 (en) 2013-11-08 2017-04-25 Promentis Pharmaceuticals, Inc. Substituted N-acetyl-L-cysteine derivatives and related compounds

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040057983A1 (en) * 2002-09-25 2004-03-25 David Schmidt Biomolecular wearable apparatus
WO2005017094A2 (en) * 2003-08-19 2005-02-24 Bioadvantex Pharma Inc. N-acetyl compositions as adjunct therapy for treatment and prevention of cysteine/glutathione deficiency
AU2007308742A1 (en) * 2006-10-23 2008-05-02 The Mental Health Research Institute Of Victoria Combination therapy
US7829709B1 (en) * 2007-08-10 2010-11-09 Marquette University Cysteine prodrugs to treat schizophrenia and drug addiction
IL188681A0 (en) * 2008-01-09 2008-12-29 Amino Acid Solutions Inc Pharmaceutical compositions and methods utilizing a d-amino acid
WO2009100431A1 (en) * 2008-02-07 2009-08-13 Marquette University Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings
US8602961B2 (en) * 2008-05-15 2013-12-10 Lifewave Products Llc Apparatus and method of stimulating elevation of glutathione levels in a subject
AU2010248758A1 (en) * 2009-05-15 2011-11-24 Intermune, Inc. Methods of treating HIV patients with anti-fibrotics
US20120041066A1 (en) * 2010-08-16 2012-02-16 Lombard Jay L Medical foods for the treatment of developmentally-based neuropsychiatric disorders via modulation of brain glycine and glutathione pathways
US8355927B2 (en) 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
US20120270860A1 (en) * 2011-04-19 2012-10-25 Gihyun Yoon Methods for treating or preventing alcohol-related disorders or craving-related disorders
JP6170166B2 (ja) 2012-10-30 2017-07-26 協和発酵バイオ株式会社 脳機能低下の予防または改善剤
JP2017534673A (ja) * 2014-09-15 2017-11-24 サウンド・ファーマシューティカルズ・インコーポレイテッド 精神病性障害を治療するための方法および組成物
EP3858344A4 (en) * 2018-09-28 2022-07-06 Keio University MARKERS FOR EVALUATION OF SENSITIVITY TO AN ANTI-CANCER COMBINATION AGENT
CN114786689A (zh) * 2019-11-18 2022-07-22 雀巢产品有限公司 用于在脑健康中使用的谷胱甘肽增强的组合物和方法
FR3119093B3 (fr) * 2021-01-27 2023-02-10 Nestle Sa Compositions et procedes pour une utilisation dans l’augmentation de la performance motivationnelle

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998029375A1 (en) * 1996-12-26 1998-07-09 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Brain targeted low molecular weight hydrophobic antioxidant compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5922765A (en) * 1996-01-18 1999-07-13 Fleming & Company, Pharmaceuticals Methods and compositions for the prevention and treatment of muscle cramps and improving muscular strength
US6149925A (en) * 1998-11-05 2000-11-21 Color Access, Inc. Topical compositions for enhancing glutathione production
US6329430B1 (en) * 1999-08-18 2001-12-11 Thomas Jefferson University Modulation of N-methyl-D-aspartate receptor responses with S-substituted derivatives of glutathione
US20020002146A1 (en) * 2000-02-11 2002-01-03 Halevie-Goldman Brian D. Compositions and methods for the production of S-adenosylmethionine within the body
US20020002136A1 (en) * 2000-06-28 2002-01-03 Hebert Rolland F. Salts of glutathione
US6812248B2 (en) * 2000-07-05 2004-11-02 John Hopkins University School Of Medicine Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB2368339B (en) * 2000-10-26 2002-09-18 Yissum Res Dev Co Complex incorporating a plurality of antioxidants

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998029375A1 (en) * 1996-12-26 1998-07-09 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Brain targeted low molecular weight hydrophobic antioxidant compounds

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9630937B2 (en) 2013-11-08 2017-04-25 Promentis Pharmaceuticals, Inc. Substituted N-acetyl-L-cysteine derivatives and related compounds
US10112897B2 (en) 2013-11-08 2018-10-30 Promentis Pharmaceuticals, Inc. Substituted N-acetyl-L-cysteine derivatives and related compounds
US10358414B2 (en) 2013-11-08 2019-07-23 Promentis Pharmaceuticals, Inc. Substituted N-acetyl-L-cysteine derivatives and related compounds
US10961187B2 (en) 2013-11-08 2021-03-30 Promentis Pharmaceuticals, Inc. Substituted N-acetyl-L-cysteine derivatives and related compounds

Also Published As

Publication number Publication date
ES2346859T3 (es) 2010-10-21
WO2003026684A1 (en) 2003-04-03
EP1438063A4 (en) 2006-05-31
CA2461703C (en) 2011-04-05
JP4684553B2 (ja) 2011-05-18
JP2010215646A (ja) 2010-09-30
US20130065961A1 (en) 2013-03-14
US20180177839A1 (en) 2018-06-28
EP1438063B1 (en) 2010-05-19
CA2461703A1 (en) 2003-04-03
DK1438063T3 (da) 2010-08-30
JP2013234193A (ja) 2013-11-21
ATE468129T1 (de) 2010-06-15
US20050032708A1 (en) 2005-02-10
DE60236446D1 (de) 2010-07-01
JP5736421B2 (ja) 2015-06-17
JP2005508333A (ja) 2005-03-31
EP1438063A1 (en) 2004-07-21

Similar Documents

Publication Publication Date Title
US20130065961A1 (en) Modulation of physiological processes and agents useful for same
AU2002333018A1 (en) Modulation of physiological processes and agents useful for same
Ebrahimi-Fakhari et al. Protein degradation pathways in Parkinson’s disease: curse or blessing
US20230042914A1 (en) Compositions and methods for treatment of homocystinuria
US20020051777A1 (en) Method of modulating cellular activity
AU757358B2 (en) A method of modulating cellular activity
US20080103204A1 (en) Method of modulating cellular activity and agents useful for same
Wu et al. Cardioprotective effects of low-dose combination therapy with rosuvastatin and fasudil in the isolated rat heart
CN120463815A (zh) 多肽偶联物及其在射血分数保留的心衰中的应用
WO2014108812A2 (en) Glycine and folate as treatment for sideroblastic anemia
US20060111286A1 (en) Method of modulating endothelial cell activity
AU2003258356B2 (en) A method of modulating endothelial cell activity
CA2595469A1 (en) A method of treating cellular damage
US20070265196A1 (en) Method of Modulating Pro-Inflammatory and Inflammatory Activity Mediated by C-Reactive Protein
AU744333B2 (en) Compositions of leukaemia inhibitory factor
AU2006201939B2 (en) A method of modulating cellular activity
AU2004221792B2 (en) A method of modulating smooth muscle cell functioning by modulating sphingosine kinase mediated signalling
AU2003222681B8 (en) A method of treatment
CA2612644A1 (en) Modulation of sphingosine kinase signalling
AU720327B2 (en) A method for the prophylaxis and treatment of an autoimmune disease
AU2005207081A1 (en) A method of modulating pro-inflammatory and inflammatory activity mediated by C-reactive protein
AU2006261583A1 (en) Modulation of sphingosine kinase signalling
CA2519359A1 (en) A method of modulating smooth muscle cell functioning by modulating sphingosine kinase mediated signalling
WO2003094903A1 (en) A method of treatment
WO2012142666A1 (en) Method of modulating amine oxidase activity and agents useful for same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO FILE SEARCH RESULTS HAS BEEN EXTENDED TO 11 JAN 2007.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 26 SEP 2012 TO 26 APR 2013 IN WHICH TO PAY A RENEWAL FEE HAS BEEN FILED .

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY A RENEWAL FEE HAS BEEN EXTENDED TO 26 APR 2013 .

MK14 Patent ceased section 143(a) (annual fees not paid) or expired